Abstract
A phase I trial that evaluated for extrahematopoietic toxicity was conducted with iodine-131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade ...Continue Reading
Citations
Jun 12, 2002·Bone Marrow Transplantation·J M PagelO W Press
Nov 5, 2005·Acta Haematologica·Xingwei SuiOliver Press
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Buck E RogersDonald J Buchsbaum
Feb 8, 2008·Cancer Immunology, Immunotherapy : CII·Mala ChakrabortyJames W Hodge
Dec 2, 2017·Oncotarget·In Ho SongIk Joon Choi
Jan 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M TamuraS V Kashmiri
Apr 18, 2003·Cancer Immunology, Immunotherapy : CII·David M Goldenberg
Apr 2, 2002·World Journal of Gastroenterology : WJG·Feng-Tian HeYan Zhang
May 19, 2006·Cancer Biotherapy & Radiopharmaceuticals·Paul C ChinnGary Braslawsky
Oct 17, 2018·Expert Opinion on Pharmacotherapy·Jennifer L Olson, Richard J Bold
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·G PavlinkovaS K Batra
Sep 5, 2003·Cancer Biotherapy & Radiopharmaceuticals·Ruby MeredithAlbert LoBuglio
Nov 9, 2011·Nature Reviews. Clinical Oncology·Jean-Pierre PougetDavid Azria
May 4, 2013·Immunotherapy·Isabelle Navarro-TeulonJean-Pierre Pouget
Mar 28, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Amber Draper
Mar 28, 2002·Cancer Biotherapy & Radiopharmaceuticals·Hazel Breitz
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Sui ShenAlbert F LoBuglio
Mar 15, 2011·Immunotherapy·Robert M Sharkey, David M Goldenberg
Jan 11, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Michael B TomblynPaul E Wallner
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Andres ForeroFrancisco Robert
Apr 7, 2011·Molecular Cancer Therapeutics·Robert M SharkeyDavid M Goldenberg
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rhona SteinDavid M Goldenberg
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carol M RichmanGerald L DeNardo
Feb 20, 1999·Protein Expression and Purification·L LinS Pestka
Mar 4, 2000·Molecular Immunology·M IwahashiS V Kashmiri
May 7, 2003·Peptides·Gabriela PavlinkovaJanina Baranowska-Kortylewicz
Mar 23, 2000·Seminars in Radiation Oncology·D E Milenic
Nov 8, 2011·Bioconjugate Chemistry·Huma MohsinMichael R Lewis
Mar 30, 2011·Bioconjugate Chemistry·Kai-Chuan ChenSteve R Roffler
Mar 16, 2006·Bioconjugate Chemistry·Huma MohsinMichael R Lewis